Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy
Kaitlyn Shaw(Translational Therapeutics (United States)), Bruce Carleton(University of British Columbia), Shinya Ito(Kyoto Sangyo University), Colin J.D. Ross(BC Children's Hospital), Lawrence J. Lesko(University of Florida), Jacques Turgeon(Unknown), Ursula Amstutz(University of Bern), Richard B. Kim(Western University), Véronique Michaud(Research & Development Institute), Soomi Hwang(University of British Columbia)
Cited by 77
Related Papers
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
|Pharmaceutics|2020|237
Intramuscular Administration of AAV1-Lipoprotein Lipase <sup>S447X</sup> Lowers Triglycerides in Lipoprotein Lipase–Deficient Patients
|Arteriosclerosis Thrombosis and Vascular Biology|2008|208
Prevalence and Risk of Potential Cytochrome P450–Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy
|Annals of Pharmacotherapy|2013|186